Suppr超能文献

给予高剂量强度5-氟尿嘧啶化疗方案后免疫效应细胞功能的保存

Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.

作者信息

Weiner L M, Hudes G R, Kitson J, Walczak J, Watts P, Litwin S, O'Dwyer P J

机构信息

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111.

出版信息

Cancer Immunol Immunother. 1993;36(3):185-90. doi: 10.1007/BF01741090.

Abstract

In a phase II clinical trial of 5-fluorouracil (5FU) plus N-(phosphonacetyl)-L-aspartate (PALA) therapy administration, a number of slowly developing clinical responses were observed. Because of this, a variety of immune parameters were sequentially studied in 21 patients on this trial. Of the 21 patients studied, 20 provided sufficient samples to compare baseline with subsequent values, 10 of the 20 patients responded to treatment. Responders and non-responders did not differ in any studied parameter at baseline. After 2 months of therapy, non-specific monocyte cytotoxicity (NSMC), antibody-dependent monocyte cytotoxicity (ADMC) and natural killer (NK) activity were higher in the entire study population, but these increases were not statistically significant. When responders and non-responders were evaluated separately, it was apparent that the trend was due solely to the changes observed in the responding patient population. When mean lysis values for each patient group were determined for each studied time point, it was possible to generate a mean area under the cytotoxicity/time curve (AUC) for each studied parameter. NSMC and ADMC did not differ in responders and non-responders. However, NK activity was significantly greater by mean AUC analysis (P = 0.006) in the responding group; NK activity was maintained in the responders, but decreased in non-responders. When lymphocyte and monocyte expression of the surface markers beta 2-microglobulin, HLA-DR, CD56, HNK-1, CD16 and interleukin-2 receptor were evaluated, there were no differences among responders and non-responders at baseline by mean AUC analysis or when comparing baseline with non-baseline values. It is concluded that although baseline immunological characteristics do not identify patients who are likely to respond to weekly 5FU and PALA, treatment is not associated with deleterious effects on the immune effector function parameters evaluated in this study, there being no effects on expression of a variety of associated cell-surface molecules.

摘要

在一项5-氟尿嘧啶(5FU)联合N-(膦酰乙酰基)-L-天冬氨酸(PALA)治疗的II期临床试验中,观察到一些缓慢出现的临床反应。因此,对该试验中的21名患者依次研究了多种免疫参数。在研究的21名患者中,20名提供了足够的样本以比较基线值与后续值,这20名患者中有10名对治疗有反应。反应者和无反应者在基线时的任何研究参数上均无差异。治疗2个月后,整个研究人群的非特异性单核细胞细胞毒性(NSMC)、抗体依赖性单核细胞细胞毒性(ADMC)和自然杀伤(NK)活性均升高,但这些升高无统计学意义。当分别评估反应者和无反应者时,很明显这种趋势完全是由于反应患者群体中观察到的变化所致。当为每个研究时间点确定每个患者组的平均裂解值时,就有可能为每个研究参数生成细胞毒性/时间曲线下的平均面积(AUC)。反应者和无反应者的NSMC和ADMC无差异。然而,通过平均AUC分析,反应组的NK活性显著更高(P = 0.006);反应者的NK活性得以维持,而无反应者的NK活性降低。当评估淋巴细胞和单核细胞表面标志物β2-微球蛋白、HLA-DR、CD56、HNK-1、CD16和白细胞介素-2受体的表达时,通过平均AUC分析或比较基线值与非基线值,反应者和无反应者在基线时无差异。得出的结论是,虽然基线免疫学特征无法识别可能对每周一次的5FU和PALA有反应的患者,但治疗对本研究中评估的免疫效应功能参数没有有害影响,对多种相关细胞表面分子的表达也没有影响。

相似文献

4
Biochemical modulation of 5-fluorouracil by PALA.
Cancer Invest. 1990;8(2):261-2. doi: 10.3109/07357909009017577.
5
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
J Clin Oncol. 1992 May;10(5):747-52. doi: 10.1200/JCO.1992.10.5.747.

本文引用的文献

10
Immunosuppression by 5-fluorouracil.5-氟尿嘧啶引起的免疫抑制
Cancer. 1970 Oct;26(4):884-9. doi: 10.1002/1097-0142(197010)26:4<884::aid-cncr2820260422>3.0.co;2-s.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验